Grant: CIHR Fellowship
Direct Payment
$60,000.00
Quantitative Plasma Genotyping as a Biomarker of Treatment Response in Advanced NSCLC
FY 2014-15
Summary
Background: The use of new therapies in advanced non-small cell lung cancer (NSCLC) has been limited by the need for multiple invasive biopsies to assess the genetic mutations present in a patient's tumor. Noninvasive plasma genotyping is a novel blood test capable of overcoming this limitation. We have recently developed a new quantitative plasma genotyping test that can measure the level of tumor DNA in a blood sample. We have optimized it to detect key mutations in advanced NSCLC. In this study, we propose to use a large group of patients to evaluate which factors affect the accuracy of this new blood test as well as whether this blood test can be used to quickly detect whether a patient is responding to a new treatment.
Objectives: To identify factors which predict patients where this blood test is most accurate as well as demonstrate the usefulness of quantitative plasma genotyping as a marker of patients who are responding to treatment.
Research Strategy: We have initiated a 300 person study of our new plasma genotyping blood test. The patients in this study will all have advanced NSCLC and be starting a new treatment. Each patient undergoes an initial blood test before beginning treatment with a new line of therapy followed by repeat blood testing and then a repeat CT scan to determine if their current treatment is effective against their tumor. Changes in the level of detectable tumor DNA after starting treatment will then be correlated with change in tumor size as well as how long each patient remains on treatment before their tumor starts to grow again.
Impact: This study will identify the patient group in which this new blood test can be used most effectively to detect mutations in a patient's tumor without a biopsy in order to select effective treatment. This study will also determine whether the level of tumor DNA that this blood test detect can be used to rapidly determine if a patient's tumor is responding to a new treatment.
Department
Program
CIHR Fellowship
Recipient
Location
Massachusetts, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
318940
Name
Sacher Adrian G
Region
Massachusetts
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Clinical
Prcname2
Health Professional Awards - Fellowships
Projecttitle
Quantitative Plasma Genotyping as a Biomarker of Treatment Response in Advanced NSCLC
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$60,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Genomics; Nsclc; Plasma Genotyping; Targeted Therapy
Abstract
Background: The use of new therapies in advanced non-small cell lung cancer (NSCLC) has been limited by the need for multiple invasive biopsies to assess the genetic mutations present in a patient's tumor. Noninvasive plasma genotyping is a novel blood test capable of overcoming this limitation. We have recently developed a new quantitative plasma genotyping test that can measure the level of tumor DNA in a blood sample. We have optimized it to detect key mutations in advanced NSCLC. In this study, we propose to use a large group of patients to evaluate which factors affect the accuracy of this new blood test as well as whether this blood test can be used to quickly detect whether a patient is responding to a new treatment.
Objectives: To identify factors which predict patients where this blood test is most accurate as well as demonstrate the usefulness of quantitative plasma genotyping as a marker of patients who are responding to treatment.
Research Strategy: We have initiated a 300 person study of our new plasma genotyping blood test. The patients in this study will all have advanced NSCLC and be starting a new treatment. Each patient undergoes an initial blood test before beginning treatment with a new line of therapy followed by repeat blood testing and then a repeat CT scan to determine if their current treatment is effective against their tumor. Changes in the level of detectable tumor DNA after starting treatment will then be correlated with change in tumor size as well as how long each patient remains on treatment before their tumor starts to grow again.
Impact: This study will identify the patient group in which this new blood test can be used most effectively to detect mutations in a patient's tumor without a biopsy in order to select effective treatment. This study will also determine whether the level of tumor DNA that this blood test detect can be used to rapidly determine if a patient's tumor is responding to a new treatment.
Competitiondate
201411
Approvedterm2
1 yr 0 mth
Pinamesdelim
Sacher, Adrian G
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $60,000~ $0~